Previous 10 | Next 10 |
home / stock / glaxf / glaxf news
Summary Third Point recently acquired a significant position in Colgate-Palmolive. The investment fits several important criteria in the current investment environment. The stage is set for Colgate to deliver several years of outsized earnings growth. Colgate’s valu...
Summary Third Point LLC is an SEC-registered investment adviser based in New York. The firm was founded in 1995 by Daniel S. Loeb, who serves as Chief Executive Officer. Third Point focuses on event-driven, value-oriented investing. During the Third Quarter, Third Point returned -...
Summary Updated results from Part A of the phase 2 MARCH study using both VIR-2218 and VIR3434 for Hepatitis B treatment are expected in the 2nd half of 2022. Results from the ongoing phase 2 study using VIR-2218 alone as a monotherapy and in combination with PEG-IFN-a for Hepatit...
Summary Investors are flocking to USD, and most foreign currencies are now weak. On the surface, investment implications seem slight, but it is quite the contrary. This article will highlight the current market implications and ways that a strong USD influences foreign assets....
Summary Sartorius stock has corrected by 55% over the last 12 months, visibly underperforming its peers and the pharmaceutical companies. Despite this, we rate the shares as neutral and stay on the sidelines until order visibility improves. We believe that the business will co...
Summary Initiation of phase 1 study of first clinical drug AL044 targeting MS4A for Alzheimer's Disease has been achieved. AbbVie for now remains committed with Alector in advancing AL002, which targets TREM2 for Alzheimer's Disease, in the ongoing INVOKE-2 phase 2 study. The ...
Summary Following the breakthrough deal with GlaxoSmithKline, Spero is in a comfortable position to advance its pipeline. The $150 million non-performance related milestone payment, equivalent to $3.2 per share, associated with Phase 3 clinical trial provides sufficient upside fro...
Summary The Zantac lawsuit will have minimal impact on Teva Pharmaceutical's financial position. At the end of August 2022, the company received approval in Europe for Ranivisio, which is a biosimilar of Lucentis, which is a medicine used to treat patients with certain. Teva P...
Summary I'm launching the first edition of the UK Top 40 High-Yield Blue-Chip Stocks list. The list is based on stocks from the FTSE 100 and FTSE 250. Given the weak economic backdrop, it shouldn't be a complete surprise that the average dividend yield across this list of stoc...
GSK plc (GSK) Citi's 17th Annual BioPharma Conference September 7, 2022, 01:50 PM ET Company Participants Roger Connor - President, Global Vaccines & Global Health Phil Dormitzer - Senior Vice President, Head of Vaccines R&D Conference Call Participants...
News, Short Squeeze, Breakout and More Instantly...
New York City, NY:March 27, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Color Ultrasonic Diagnostic Apparatus Market in Global Industry: 2020 Research and New Innovations in Medical Devices Sector. The prime objective of the report is to ...
New York City, NY:March 27, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Chemical Mechanical Planarization Slurries Market in Global Industry: 2020 Research and New Innovations in Chemicals and Materials Sector. The prime objective of the ...